Article
Real-world data on the efficacy and safety of tezacaftor-ivacaftor in adults living with cystic fibrosis homozygous for F508del and heterozygous for F508del and a residual function mutation.
Acta clinica Belgica - 1 Aug 2023
Vincken Stefanie, Verbanck Sylvia, Braun Sue, Buyck Nathalie, Knoop Christiane, Vanderhelst Eef
Abstract excerpt
BACKGROUND: To examine safety and efficacy of tezacaftor-ivacaftor (TEZ/IVA) in a real-life setting in adults living with cystic fibrosis. METHODS: A multicentre retrospective observational study, including adults living with cystic fibrosis (pwCF) eligible for TEZ/IVA, with assessments at baseline, 3 months (visit3mo) and 6 months (visit6mo) after start of treatment. Outcomes included change in FEV1, LCI, FeNO,...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.